Fate Therapeutics FATE
NASDAQ FATE
$2.48 +0.06 (+2.48%)
As of: Sep 4, 2026 · 3:59 PM EDT

Fate Therapeutics (FATE) Operating Margin (QoQ) (2012 - 2026)

Analysis

Fate Therapeutics (FATE) Operating Margin (QoQ) (2012 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn
10 Fate Therapeutics 299.79 Mn 299.79 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 104,503.00
Mar 31, 2026 -418.00
Dec 31, 2025 -54,111.00
Sep 30, 2025 -5,658.00
Jun 30, 2025 59,553.00
Mar 31, 2025 78,571.00
Dec 31, 2024 -161,591.00
Sep 30, 2024 -103,814.00
Jun 30, 2024 198,716.00
Mar 31, 2024 21,555.00
Dec 31, 2023 -23,063.00
Sep 30, 2023 406,798.00
Jun 30, 2023 -665,731.00
Mar 31, 2023 9,675.00
Dec 31, 2022 43,144.00
Sep 30, 2022 -12,862.00
Jun 30, 2022 -4,365.00
Mar 31, 2022 208.00
Dec 31, 2021 -2,249.00
Sep 30, 2021 -3,521.00